U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Center for Substance Abuse Treatment. Incorporating Alcohol Pharmacotherapies Into Medical Practice: A Review of the Literature. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2009. (Treatment Improvement Protocol (TIP) Series, No. 49s.)

Cover of Incorporating Alcohol Pharmacotherapies Into Medical Practice: A Review of the Literature

Incorporating Alcohol Pharmacotherapies Into Medical Practice: A Review of the Literature.

Show details

3General Bibliography

  1. Aithal GP, Thornes H, Dwarakanath AD, Tanner AR. Measurement of carbohydrate-deficient transferrin (CDT) in a general medical clinic: Is this test useful in assessing alcohol consumption? Alcohol and Alcoholism. 1998;33(3):304–309. [PubMed: 9632056]
  2. Alcoholics Anonymous. The AA member—Medications and other drugs: Report from a group of physicians in AA. New York: Alcoholics Anonymous World Services; 1984.
  3. American Society of Addiction Medicine. Patient placement criteria for the treatment of substance use disorders: ASAM-PPC-2R. Chevy Chase, MD: Author; 2001. 2nd revised ed.
  4. Anton RF, Oroszi G, O’Malley SS, Couper D, Swift R, Pettinati H, et al. An evaluation of μ-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: Results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Archives of General Psychiatry. 2008;65(2):135–144. [PMC free article: PMC2666924] [PubMed: 18250251]
  5. Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. The Alcohol Use Disorders Identification Test: Guidelines for use in primary care. 2nd ed. Geneva, Switzerland: World Health Organization Department of Mental Health and Substance Abuse; 2001.
  6. Bell H, Tallaksen CM, Try K, Haug E. Carbohydrate-deficient transferrin and other markers of high alcohol consumption: A study of 502 patients admitted consecutively to a medical department. Alcoholism: Clinical and Experimental Research. 1994;18(5):1103–1108. [PubMed: 7847591]
  7. Bjornsson E, Nordlinder H, Olsson R. Clinical characteristics and prognostic markers in disulfiram-induced liver injury. Journal of Hepatology. 2006;44:791–797. [PubMed: 16487618]
  8. Bohn MJ, Krahn DD, Staehler BA. Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcoholism: Clinical and Experimental Research. 1995;19(3):600–606. [PubMed: 7573780]
  9. Buonopane A, Petrakis IL. Pharmacotherapy of alcohol use disorders. Substance Use & Misuse. 2005;40:2001–2020. [PubMed: 16282090]
  10. Carroll KM, Fenton LR, Ball SA, Nich C, Frankforter TL, Shi JS, et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients. Archives of General Psychiatry. 2004;61:264–271. [PMC free article: PMC3675448] [PubMed: 14993114]
  11. Center for Substance Abuse Treatment. The role and current status of patient placement criteria in the treatment of substance use disorders. Rockville, MD: Substance Abuse and Mental Health Services Administration; 1995. Treatment Improvement Protocol Series 13. HHS Publication No. (SMA) 00–3403.
  12. Center for Substance Abuse Treatment. A guide to substance abuse services for primary care physicians. Rockville, MD: Substance Abuse and Mental Health Services Administration; 1997. Treatment Improvement Protocol Series 24. HHS Publication No. (SMA) 03–3807. [PubMed: 22514830]
  13. Center for Substance Abuse Treatment. Brief interventions and brief therapies for substance abuse. Rockville, MD: Substance Abuse and Mental Health Services Administration; 1999. Treatment Improvement Protocol Series 34. HHS Publication No. (SMA) 99–3353. [PubMed: 22514840]
  14. Center for Substance Abuse Treatment. Enhancing motivation for change in substance abuse treatment. Rockville, MD: Substance Abuse and Mental Health Services Administration; 1999. Treatment Improvement Protocol Series 35. HHS Publication No. (SMA) 02–3693. [PubMed: 22514841]
  15. Center for Substance Abuse Treatment. KAP keys for clinicians based on TIP 34: Brief interventions and brief therapies for substance abuse. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2001. HHS Publication No. (SMA) 01–3601.
  16. Center for Substance Abuse Treatment. KAP keys for clinicians based on TIP 35: Enhancing motivation for change in substance abuse treatment. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2001. HHS Publication No. (SMA) 01–3603. [PubMed: 22514841]
  17. Center for Substance Abuse Treatment. Quick guide for clinicians based on TIP 34: Brief interventions and brief therapies for substance abuse. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2001. HHS Publication No. (SMA) 01–3600.
  18. Center for Substance Abuse Treatment. Quick guide for clinicians based on TIP 35: Enhancing motivation for change in substance abuse treatment. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2001. HHS Publication No. (SMA) 01–3602. [PubMed: 22514841]
  19. Center for Substance Abuse Treatment. Substance abuse treatment for persons with co-occurring disorders. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2005. Treatment Improvement Protocol Series 42. HHS Publication No. (SMA) 05–3992. [PubMed: 22514848]
  20. Center for Substance Abuse Treatment. Detoxification and substance abuse treatment. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2006. Treatment Improvement Protocol Series 45. HHS Publication No. (SMA) 06–4131. [PubMed: 22514851]
  21. Center for Substance Abuse Treatment. The role of biomarkers in the treatment of alcohol use disorders. Substance Abuse Treatment Advisory. 2006;5(4)
  22. Chandrasekaran R, Sivaprakash B, Chitraleka V. Five years of alcohol de-addiction services in a tertiary care general hospital. Indian Journal of Psychiatry. 2001;43:58–60. [PMC free article: PMC2955934] [PubMed: 21407840]
  23. Chick J, Gough K, Falkowski W, Kershaw P, Hore B, Mehta B, et al. Disulfiram treatment of alcoholism. British Journal of Psychiatry. 1992;161:84–89. [PubMed: 1638335]
  24. Conigliaro J, Delos Reyes C, Parran TV Jr, Schulz JE. Principles of screening and early intervention. In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, editors. Principles of addiction medicine. 3rd ed. Chevy Chase, MD: American Society of Addiction Medicine; 2003. pp. 325–335.
  25. Conigliaro J, Justice AC, Gordon AJ, Bryant K. Role of alcohol in determining human immunodeficiency virus (HIV)—Relevant outcomes: A conceptual model to guide the implementation of evidence-based interventions into practice. Medical Care. 2006;44:S1–S6. [PubMed: 16849963]
  26. Crowley WF Jr, Sherwood L, Salber P, Scheinberg D, Slavkin H, Tilson H, et al. Clinical research in the United States at a crossroads: Proposal for a novel public-private partnership to establish a national clinical research enterprise. JAMA. 2004;287:1120–1126. [PubMed: 14996782]
  27. Czirr SA, Hubbell CL, Milano WE, Frank JM, Reid LD. Selected opioids modify intake of sweetened ethanol solution among female rats. Alcohol. 1987;4(3):157–160. [PubMed: 3036176]
  28. Deas D, May MP, Randall C, Johnson N, Anton R. Naltrexone treatment of adolescent alcoholics: An open-label pilot study. Journal of Child and Adolescent Psychopharmacology. 2005;15(5):723–728. [PubMed: 16262589]
  29. De Sousa A, De Sousa A. A one-year pragmatic trial of naltrexone vs. disulfiram in the treatment of alcohol dependence. Alcohol & Alcoholism. 2004;39(6):528–531. [PubMed: 15525790]
  30. Edenberg HJ. The collaborative study on the genetics of alcoholism: An update. Alcohol Research & Health. 2002;26:214–218. [PMC free article: PMC6683843] [PubMed: 12875050]
  31. Escobar F, Espi F, Canteras M. Diagnostic tests for alcoholism in primary health care: Compared efficacy of different instruments. Drug and Alcohol Dependence. 1995;40(2):151–158. [PubMed: 8745137]
  32. Gordon AJ, Wentz CM, Gibbon JL, Mason AD, Freyder PJ, O’Toole TP. Relationships between patient characteristics and unsuccessful substance abuse detoxification. Journal of Addictive Diseases. 2001;20(2):41–53. [PubMed: 11318396]
  33. Hald J, Jacobsen E. A drug sensitising the organism to ethyl alcohol. Lancet. 1948;2:1001–1004. [PubMed: 18103475]
  34. Harwood H. Updating estimates of the economic costs of alcohol abuse in the United States: Estimates, update methods, and data. Rockville, MD: National Institute on Alcohol Abuse and Alcoholism; 2000. Retrieved July 20, 2006, from http://pubs​.niaaa.nih​.gov/publications/economic-2000.
  35. Hernandez-Avila CA, Song C, Kuo L, Tennen H, Armeli S, Kranzler HR. Targeted versus daily naltrexone: Secondary analysis of effects on average daily drinking. Alcoholism: Clinical and Experimental Research. 2006;30(5):860–865. [PubMed: 16634855]
  36. Hoffman PL, Morrow L, Phillips TJ, Siggins GR.2000Neuroadaptation to ethanol at the molecular and cellular levels Noronha A, Eckardt M, Warren K, editors. Review of NIAAA’s neuroscience and behavioral research portfolio NIH Publication No. 00–45785–188.NIAAA Research Monograph No. 34 Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism;
  37. Hubbell CL, Czirr SA, Hunter GA, Beaman CM, LeCann NC, Reid LD. Consumption of ethanol solution is potentiated by morphine and attenuated by naloxone persistently across repeated daily administrations. Alcohol. 1986;3(1):39–54. [PubMed: 3964437]
  38. Kiefer F, Holger J, Tarnaske T, Helwig H, Briken P, Holzbach R, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism. Archives of General Psychiatry. 2003;60(1):92–99. [PubMed: 12511176]
  39. Killeen TK, Brady KT, Gold PB, Simpson KN, Faldowski RA, Tyson C, et al. Effectiveness of naltrexone in a community treatment program. Alcoholism: Clinical and Experimental Research. 2004;28(11):1710–1717. [PubMed: 15547458]
  40. Kim SW, Grant JE, Adson DE, Remmel RP. A preliminary report on possible naltrexone and nonsteroidal analgesic interactions. Journal of Clinical Psychopharmacology. 2001;21:632–634. [PubMed: 11763022]
  41. King AC, Schluger J, Gunduz M, Borg L, Perret G, Ho A, et al. Hypothalamic-pituitary-adrenocortical (HPA) axis response and biotransformation of oral naltrexone: Preliminary examination of relationship to family history of alcoholism. Neuropsychopharmacology. 2002;26(6):778–788. [PubMed: 12007748]
  42. Krampe H, Stawicki S, Wagner T, Bartels C, Aust C, Rüther E, et al. Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: Impact of alcohol deterrents on outcome. Alcoholism: Clinical and Experimental Research. 2006;30:86–95. [PubMed: 16433735]
  43. Kranzler HR, Armeli S, Tennen H, Blomqvist O, Oncken C, Petry N, et al. Targeted naltrexone for early problem drinkers. Journal of Clinical Psychopharmacology. 2003;23(3):294–304. [PubMed: 12826991]
  44. Kranzler HR, Littleton J. Neuropharmacology of opioid antagonists and acamprosate. Symposium III: Pharmacotherapy of Alcoholism; Presentation at the American Academy of Addiction Psychiatry 13th Annual Meeting and Symposium; Las Vegas, NV. Dec, 2002.
  45. Kranzler HR, Rosenthal RN. Dual diagnosis: Alcoholism and co-morbid psychiatric disorders. American Journal on Addiction. 2003;12(Suppl 1):S26–S40. [PubMed: 14972778]
  46. Kristenson H. How to get the best out of Antabuse. Alcohol and Alcoholism. 1995;30:775–783. [PubMed: 8679019]
  47. Mark TL, Kranzler HR, Song X, Bransberger P, Poole VH, Crosse S. Physicians’ opinions about medications to treat alcoholism. Addiction. 2003;98:617–626. [PubMed: 12751979]
  48. Martin B, Mangum L, Beresford TP. Use of court-ordered supervised disulfiram therapy at DVA Medical Centers in the United States. American Journal on Addictions. 2005;14:208–212. [PubMed: 16019971]
  49. Mason BJ. Rationale for combining acamprosate and naltrexone for treating alcohol dependence. Journal of Studies on Alcohol. 2005;(Suppl 15):148–156. [PubMed: 16223066]
  50. Maxwell S, Shinderman MS. Use of naltrexone in the treatment of alcohol use disorders in patients with concomitant major mental illness. Journal of Addictive Diseases. 2000;19(3):61–96. [PubMed: 11076120]
  51. McCaul ME, Petry NM. The role of psychosocial treatments in pharmacotherapy for alcoholism. American Journal on Addiction. 2003;12(Suppl 1):S41–S52. [PubMed: 14972779]
  52. McCaul ME, Wand GS, Eissenberg T, Rohde CA, Cheskin LJ. Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects. Neuropsychopharmacology. 2000;22(5):480–492. [PubMed: 10731623]
  53. McCaul ME, Wand GS, Rohde C, Lee SM. Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers. Alcoholism: Clinical and Experimental Research. 2000;24(9):1385–1391. [PubMed: 11003204]
  54. McKay JR. Is there a case for extended interventions for alcohol and drug use disorders? Addiction. 2005;100:1594–1610. [PubMed: 16277622]
  55. McLellan AT, Lewis DC, O’Brien CP, Kleber HD. Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284(13):1689–1695. [PubMed: 11015800]
  56. Merrill JO, Jackson TR, Schulman BA, Saxon AJ, Awan A, Kapitan S, et al. Methadone medical maintenance in primary care: An implementation evaluation. Journal of General Internal Medicine. 2005;20:344–349. [PMC free article: PMC1490098] [PubMed: 15857492]
  57. National Institute on Alcohol Abuse and Alcoholism. Medical management treatment manual: A clinical research guide for medically trained clinicians providing pharmacotherapy as part of the treatment for alcohol dependence. Vol. 2. Bethesda, MD: Author; 2004. COMBINE Monograph Series.
  58. National Institute on Alcohol Abuse and Alcoholism. Helping patients who drink too much: A clinician’s guide. Bethesda, MD: Author; 2006.
  59. Nuwayser ES, DeRoo DJ, Balskovich PD, Tsuk AG. Rockville, MD: National Institute on Drug Abuse; Sustained release injectable naltrexone microcapsules. 1990:532–533. NIDA Research Monograph 105. [PubMed: 1908558]
  60. Office of Applied Studies. Results from the 2005 National Survey on Drug Use and Health: National findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2006. NSDUH Series H-30. HHS Publication No. (SMA) 06‐4194.
  61. O’Malley SS, Kosten TR. Pharmacotherapy of addictive disorders. In: Miller WR, Carroll KM, editors. Rethinking substance abuse: What the science shows, and what we should do about it. New York: Guilford; 2006. pp. 240–256.
  62. O’Malley SS, Krishnan-Sarin S, Farren C, O’Connor PG. Naltrexone‐induced nausea in patients treated for alcohol dependence: Clinical predictors and evidence for opioid-mediated effects. Journal of Clinical Psychopharmacology. 2000;20(1):69–76. [PubMed: 10653211]
  63. Ooteman W, Verheul R, Naassila M, Daoust M, Schippers GM, Koeter MWJ, et al. Patient-treatment matching with anti-craving medications in alcohol-dependent patients: A review on phenotypic, endophenotypic and genetic indicators. Journal of Substance Use. 2005;10(2–3):75–96.
  64. Oscar-Berman M, Marinkovic K. Alcoholism and the brain: An overview. Alcohol Research & Health. 2003;27:125–133. [PMC free article: PMC6668884] [PubMed: 15303622]
  65. Oslin DW, Pettinati HM, Volpicelli JR, Wolf AL, Kampman KM, O’Brien CP. The effects of naltrexone on alcohol and cocaine use in dually addicted patients. Journal of Substance Abuse Treatment. 1999;16(2):163–167. [PubMed: 10023615]
  66. Pettinati HM, Volpicelli JR, Pierce JD, O’Brien CP. Improving naltrexone response: An intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. Journal of Addictive Diseases. 2000;19(1):71–83. [PubMed: 10772604]
  67. Ramoz N, Schumann G, Gorwood P. Genetic and pharmacogenetic aspects of alcohol-dependence. Current Pharmacogenomics. 2006;4:19–32.
  68. Reid LD, Czirr SA, Bensinger CC, Hubbell CL, Volanth AJ. Morphine and diprenorphine together potentiate intake of alcoholic beverages. Alcohol. 1987;4(3):161–168. [PubMed: 3036177]
  69. Reid LD, Delconte JD, Nichols ML, Bilsky EJ, Hubbell CL. Tests of opioid deficiency hypotheses of alcoholism. Alcohol. 1991;8(4):247–257. [PubMed: 1651735]
  70. Roozen HG, de Waart R, van der Windt D, van den Brink W, de Jong C, Kerkhof A. A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence. European Neuropsychopharmacology. 2006;16:311–323. [PubMed: 16361086]
  71. Rubio G, Ponce G, Rodriguez-Jimenez R, Jimenez-Arriero MA, Hoenicka J, Polomo T. Clinical predictors of response to naltrexone in alcoholic patients: Who benefits most from treatment with naltrexone? Alcohol and Alcoholism. 2005;40(3):227–233. [PubMed: 15797885]
  72. Schuckit MA. Drug and alcohol abuse: A clinical guide to diagnosis and treatment. 6th ed. New York: Springer; 2006. Rehabilitation; pp. 334–383.
  73. Sharon AC, Wise DL. Development of drug delivery systems for use in treatment of narcotic addiction. Rockville, MD: National Institute on Drug Abuse; 1981. p. 194.p. 213. NIDA Research Monograph 28. [PubMed: 6791005]
  74. Sillanaukee P, Aalto M, Seppa K. Carbohydrate-deficient transferrin and conventional alcohol markers as indicators for brief intervention among heavy drinkers in primary health care. Alcoholism: Clinical and Experimental Research. 1998;22(4):892–896. [PubMed: 9660318]
  75. Sorvajarvi K, Blake JE, Israel Y, Niemela O. Sensitivity and specificity of carbohydrate-deficient transferrin as a marker of alcohol abuse are significantly influenced by alterations in serum transferrin: Comparison of two methods. Alcoholism: Clinical and Experimental Research. 1996;20(3):449–454. [PubMed: 8727236]
  76. Spanagel R, Zieglgansberger W. Anti-craving compounds for ethanol: New pharmacological tools to study addictive processes. Trends in Pharmacological Sciences. 1997;18(2):54–59. [PubMed: 9090311]
  77. Thomson Healthcare, Inc. Physicians’ desk reference. 60th ed. Montvale, NJ: Thomson PDR; 2006. pp. 1175–1177.
  78. Thornquist L, Biros M, Olander R, Sterner S. Health care utilization of chronic inebriates. Academic Emergency Medicine. 2002;9(4):300–308. [PubMed: 11927454]
  79. Volpicelli JR, Watson NT, King AC, Sherman CE, O’Brien CP. Effect of naltrexone on alcohol “high” in alcoholics. American Journal of Psychiatry. 1995;152(4):613–615. [PubMed: 7694913]
  80. Weiss RD. Adherence to pharmacotherapy in patients with alcohol and opioid dependence. Addiction. 2004;99:1382–1392. [PubMed: 15500591]
  81. Whitlock EP, Polen MR, Green CA, Orleans T, Klein J. Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: A summary of the evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine. 2004;140:557–568. [PubMed: 15068985]
  82. Williams SH. Medications for treating alcohol dependence. American Family Physician. 2005;72:1775–1780. [PubMed: 16300039]
  83. Yersin B, Nicolet JF, Dercrey H, Burnier M, van Melle G, Pecoud A. Screening for excessive alcohol drinking: Comparative value of carbohydrate-deficient transferrin, gamma-glutamyltransferase, and mean corpuscular volume. Archives of Internal Medicine. 1995;155(17):1907–1911. [PubMed: 7677558]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (725K)

Other titles in these collections

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...